NCT05500391RecruitingPhase 2
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring
Source: ClinicalTrials.gov · Last updated 18 Mar 2026
Brief summary (registry, in English)
This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (\<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan, established for each patient according to national guidelines, when the surveillance is conducted in person by a hospital-based physician (control arm) or remotely by a trained nurse (experimental arm).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (estimated)
- First submitted
- 10 Aug 2022
- Start date
- 28 Feb 2024
- Primary completion date
- Oct 2026
- Lead sponsor
- Centre Oscar Lambret
- Diseases
- Neuroendocrine tumours, Ovarian cancer, Sarcoma
- NCT number
- NCT05500391
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 88
- From 28 Feb 2024 to the primary completion date, Oct 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Contraindication to imaging tests required for the surveillance plan
- No telephone
- Patient under guardianship or curatorship
Who the study is looking for
- Positive diagnosis (anatomopathology) of tumor within 12 months
- Patient 18 years of age or older
- Patient with one of the following conditions:
- Desmoid fibromatosis of the abdominal wall operated on or under active surveillance
- Stage I testicular seminoma (whether or not treated with carboplatin AUC7)
- Stage I non-seminomatous germ cell tumor (with or without adjuvant BEP chemotherapy)
- Operated GIST with low risk of relapse
- Rare gynecological tumors (sex cord and stromal tumors; germ cell tumors of the ovary, clear cell adenocarcinoma, mucinous adenocarcinoma of the ovary, borderline tumors, small cell carcinoma, ovarian and uterine carcinosarcoma, low grade serous tumors), operated
- Low-grade glioma, operated
- Low-grade neuroendocrine tumor, treated by surgery alone
- Patient who has given consent to participate in the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Amiens Coordinator of this site? Confirm its status | Amiens | France | Not yet recruiting |
| Centre François Baclesse Coordinator of this site? Confirm its status | Caen | France | Not yet recruiting |
| Centre Oscar Lambret Coordinator of this site? Confirm its status | Lille | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.